Omarigliptin (MK-3102) Good Manufacturer supply High Quality 1226781-44-7
- Molecular Formula:C17H20F2N4O3S
- Molecular Weight:398.434
- Boiling Point:529.4±60.0 °C(Predicted)
- PKA:9.11±0.60(Predicted)
- PSA：98.83000
- Density:1.61±0.1 g/cm3(Predicted)
- LogP:2.86110
Omarigliptin (MK-3102) (1226781-44-7) Usage
MK-3102 is a potent, reversible, and competitive inhibitor of dipeptidyl peptidase 4 (DPP-4; IC50 = 1.6 nM; Ki = 0.8 nM). It is selective for DPP-4 over 168 proteases, ion channels, and enzymes with IC50 values greater than 10 μM in all assays. MK-3102 significantly reduces blood glucose levels in a dose-dependent manner in vivo in rats. It also has a long half-life (11 and 22 hours in rat and dog, respectively) making it suitable for once weekly dosing. Clinical trials demonstrate that formulations containing MK-3102 reduce plasma glucose and HbA1c in patients with type 2 diabetes mellitus (T2DM).
How to get the best price on Omarigliptin (MK-3102)?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of Omarigliptin (MK-3102) . You can buy high quality, low price Omarigliptin (MK-3102) 1226781-44-7 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches
